Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-γ Activity

Michael Schupp, Joshua C. Curtin, Roy J. Kim, Andrew N. Billin and Mitchell A. Lazar
Molecular Pharmacology May 2007, 71 (5) 1251-1257; DOI: https://doi.org/10.1124/mol.106.033662
Michael Schupp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua C. Curtin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy J. Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew N. Billin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitchell A. Lazar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Nuclear receptors (NRs) are transcription factors whose activity is regulated by the binding of small lipophilic ligands, including hormones, vitamins, and metabolites. Pharmacological NR ligands serve as important therapeutic agents; for example, all-trans retinoic acid, an activating ligand for retinoic acid receptor α (RARα), is used to treat leukemia. Another RARα ligand, (E)-S,S-dioxide-4-(2-(7-(heptyloxy)-3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-benzoic acid (Ro 41-5253), is a potent antagonist that has been a useful and purportedly specific probe of RARα function. Here, we report that Ro 41-5253 also activates the peroxisome proliferator-activated receptor γ (PPARγ), a master regulator of adipocyte differentiation and target of widely prescribed antidiabetic thiazolidinediones (TZDs). Ro 41-5253 enhanced differentiation of mouse and human preadipocytes and activated PPARγ target genes in mature adipocytes. Like the TZDs, Ro 41-5253 also down-regulated PPARγ protein expression in adipocytes. In addition, Ro 41-5253 activated the PPARγ-ligand binding domain in transiently transfected HEK293T cells. These effects were not prevented by a potent RARα agonist or by depleting cells of RARα, indicating that PPARγ activation was not related to RARα antagonism. Indeed, Ro 41-5253 was able to compete with TZD ligands for binding to PPARγ, suggesting that Ro 41-5253 directly affects PPAR activity. These results vividly demonstrate that pharmacological NR ligands may have “off-target” effects on other NRs. Ro 41-5253 is a PPARγ agonist as well as an RARα antagonist whose pleiotropic effects on NRs may signify a unique spectrum of biological responses.

Footnotes

  • This work was supported by National Institutes of Health grant R01-DK49780 (to M.A.L). M.S. was supported by Mentored Fellowship award from the American Diabetes Association, and J.C.C was supported by National Institute of Diabetes and Digestive and Kidney Diseases training grants 5-F32-DK070405-03 and 5-R01-DK045780-12.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

  • doi:10.1124/mol.106.033662.

  • ABBREVIATIONS: PPAR, peroxisome proliferator-activated receptor; RAR, retinoic acid receptor; TZD, thiazolidinedione; RXR, retinoid X receptor; NR, nuclear receptors; atRA, all-trans retinoid acid; Ro 41-5253, (E)-S,S-dioxide-4-(2-(7-(heptyloxy)-3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-benzoic acid; IBMX, 3-isobutyl-1-methylxanthine; SGBS, Simpson Golabi Behmel Syndrome; LBD, ligand binding domain; aP2, adipose protein 2; GW2433, 2-(4-{3-[1-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-3-(2,3-dichloro-phenyl)-ureido]-propyl}-phenoxy)-2-methyl-propionic acid; PPRE, peroxisome proliferator-activated receptor response element; AM-580, 4-[(5,5,8,8-tetramethyl6,7-dihydronaphthalene-2-carbonyl)amino]benzoic acid.

    • Received December 19, 2006.
    • Accepted February 8, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 71 (5)
Molecular Pharmacology
Vol. 71, Issue 5
1 May 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-γ Activity
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-γ Activity

Michael Schupp, Joshua C. Curtin, Roy J. Kim, Andrew N. Billin and Mitchell A. Lazar
Molecular Pharmacology May 1, 2007, 71 (5) 1251-1257; DOI: https://doi.org/10.1124/mol.106.033662

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-γ Activity

Michael Schupp, Joshua C. Curtin, Roy J. Kim, Andrew N. Billin and Mitchell A. Lazar
Molecular Pharmacology May 1, 2007, 71 (5) 1251-1257; DOI: https://doi.org/10.1124/mol.106.033662
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Hexahydroquinoline derivatives activate ADGRG1/GPR56
  • Action of Org 34167 on HCN channels
  • The effects of echinocystic acid on Kv7 channels
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics